Linear Clinical Research Current Trials Menu

Compare Trials

Healthy Volunteer Studies

LE180604 | Heart Disease Study

Help us test a new treatment for dyslipidaemia! Otherwise known as abnormal levels of lipids in the blood (e.g. cholesterol and triglycerides). Untreated it can lead to heart disease and many other serious conditions, due to a build-up of these lipids in arteries.

You Get $3060! 

(remuneration based on completion of in-house stay and all follow-up appointments)

3 nights and 4 days with 11 follow-up visits.

EXAMPLE TIMELINES LE180604 

COHORT 1
In-house Stay Check-In 05-Jan
Check-Out 08-Jan
Appointments Day 3 09-Jan
Day 8 14-Jan
Day 15 21-Jan
Day 22 28-Jan
Day 29 04-Feb
Day 43 18-Feb
Day 57 04-Mar
Day 71 18-Mar
Day 85 01-Apr
Day 99 15-Apr
Day 113 29-Apr
  • Healthy Males and Females between the ages of 18 and 65
  • BMI must be between 19 – 37 kg/m
  • Participants will be required to have elevated triglycerides & LDL-C (found in cholesterol checks) this is tested in screening or we can look at any recent results that you provide
  • Must be on a stable diet for at least 4 weeks and over the duration of the study
  • Must not have any clinically significant illness or disease
  • Must be non-smokers (Max 2 cigarettes per month within the previous 6 months)
  • Participants must be willing to consume a high fat & high carbohydrate meal prior to dose (e.g. fried bacon, fried eggs, full fat milk)
  • Must be willing to provide stool samples

APPLY NOW

 

LE181003 | PKU Study

 

Help us trial a new treatment for phenylketonuria (PKU) and hyperphenylalaninemia (HPA). PKU is an inherited genetic condition that causes an increase in the levels of a substance called phenylalanine in the blood. If PKU is not treated, phenylalanine can build up to harmful levels in the body, leading to HPA and causing intellectual disability and other serious health problems.

You Get $900! 

Visit Schedule

2 nights and 3 days with 2 follow-up visits.

Cohort

In-House Period  Follow-Up Visits

Check-in

D -1

Check-out

D2

D8

D22

1

10-Jan 12-Jan 18-Jan 01-Feb

Inclusion Criteria

  • Healthy Males and Females between the ages of 18 and 55
  • BMI must be between 18 – 30 kg/m( > 50kg, < 100kg)
  • Volunteers must be free from any clinically significant illness
  • Must be non-smokers (Max 3 cigarettes in the last 6 months)
  • Participants must be willing to consume a standard meal prior to dosing (e.g. bread, cereal, milk and yogurt).
  • Must not have a history of food intolerance (E.g. gluten, lactose, dairy).
  • Must not have participated in our previous study LE17102

 APPLY NOW

LE180501 | Cardiovascular Disease Study

Help us test a new treatment for Cardiovascular Disease (CVD) and elevated plasma Lipoprotein(a) levels. Cardiovascular disease kills one Australian every 12 minutes (The Heart Foundation). Participating in this trial means you’ll be supporting world leading research into improving treatments.

You Get $2550! 

(remuneration based on completion of in-house stay and all follow-up appointments)

This Research is being run by a world leading expert in this area, Professor Gerald Watts.

 Example Visit Schedule

5 day stay with 11 appointments spread across 5 months 

LE180501 Study Timeline COHORT 4 Group 1
COHORT 4 Group 2
In-House Check-In 04-Dec 05-Dec
Check-Out 08-Dec 09-Dec
Follow up Day 7 11Dec 12-Dec
Day 15 19Dec 20-Dec
Day 18 22-Dec 22-Dec
Day 22 27-Dec 27-Dec
Day 29 03-Jan 03-Jan
Day 43 16-Jan 17-Jan
Day 57 30-Jan 31-Jan
Day 71 13-Feb 14-Feb
Day 85 27-Feb
28-Feb
Day 113 27-Mar
28-Mar
Day 155 08-May
09-May

 

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 60
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Body Mass Index (BMI) between 18 – 32 kg/m2
  • Elevated plasma Lipoprotein(a) level ≥70 and ≤199nmol/L, confirmed by a pre-screen blood test
  • Not currently on any medications with the exception of Statin, lipid-lowering medications (for certain cohorts only)
  • Participants must be non-smokers (Have not used any nicotine containing products in the last 6 months)

APPLY NOW

 

 

LE180901 | Asthma Study

COMING SOON

Help us research a medication for the treatment of Asthma!

You Get $5140! 

(this payment is based on completing all dates from one of the trial’s cohorts)

Visit Schedule

13 days in-house and 2 appointments

Cohort In-House Appointments
Check-In

Day-1

Check-Out

Day 12

Day 17 Day 40
3.1 07-Jan 19-Jan 23-Jan 16-Feb
3.2 09-Jan 21-Jan 27-Jan 18-Feb
3.3
21-Jan
02-Feb
07-Feb
02-Mar
3.4 22-Jan
03-Feb 08-Feb
03-Mar

 

Inclusion Criteria

  • Healthy Males and Females between the ages of 18 and 55
  • BMI must be between 18 – 35 kg/m2   
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Must have diagnosis of mild asthma. (Documented evidence needed)
  • Must be non-smokers (for at least the last 6 months)

APPLY NOW

 

LE17124 | Hearing Loss Study

ON HOLD

Investigating a new treatment for children with cancer who suffer hearing loss as a result of exposure to chemotherapy drugs. It is estimated that, on average, about 750 children aged 0-14 years old are diagnosed with cancer each year in Australia (Cancer Council). Participating in this trial means you’ll be supporting world leading research into improving hearing loss treatments for these children.

You Get $2320! 

(This payment is based on completing the in-house stay and all scheduled appointments)

Visit Schedule

2 nights and 3 days with one follow up phone call and three in-house follow-up appointments

LE17124

STUDY TIMELINES

COH 2.1 COH 2.2 COH 2.3 COH 2.4
In-House Check-In 20-Jan 30-Jan 03-Feb 10-Feb
Check-Out 22-Jan 01-Feb 05-Feb 12-Feb
Follow Up Day 4 (phone call) 24-Jan 03-Feb 07-Feb 14-Feb
Day 8 28-Jan 07-Feb 11-Feb 18-Feb
Day 15 04-Feb 14-Feb 18-Feb 25-Feb
Day 30 19-Feb 01-Mar 05-Mar 12-Mar

 

Inclusion Criteria

  • Healthy Males and Females, aged between 18 and 65
  • Body Mass Index (BMI) between 18 – 35 kg/m2
  • Normal hearing,  defined as ≤20 dB from 250 Hz to 8 kHz bilateral
  • No allergies to any local anesthetics (numbing medication)
  • Free from any clinically significant illness or disease as determined by their medical history.
  • Must be willing to attend a hearing test if eligible after first screening visit.

APPLY NOW

 

 

LE180802 | Macular Degeneration Study

ON HOLD

Help us trial a new investigational treatment for dry age-related macular degeneration (AMD) and juvenile onset macular degeneration, known as Stargardt disease (STGD). 

You Get $1600! 

(remuneration based on completion of in-house stay and all follow-up appointments)

 APPLY NOW

 Appointment Schedule

5 day, 4 nights stay, 1 appointment and a follow up phone call

Cohort In-House Phone Call Appointment
Check-In

Day-1

Dosing

Day 1

Check-Out

Day 4

Day 6 Day 8
1.1 14-Jan-19 15-Jan-19 18-Jan-19 20-Jan-19 22-Jan-19
1.2 15-Jan-19 16-Jan-19 19-Jan-19 21-Jan-19 23-Jan-19
1.3 16-Jan-19 17-Jan-19 20-Jan-19 22-Jan-19 24-Jan-19
  • Healthy Males and Females, aged between 18 and 65
  • Females must be of Non-Childbearing Potential (either Surgically Sterile or Postmenopausal)
  • Body Mass Index (BMI) between 18 – 30 kg/m2
  • Must be free from any clinically significant illness or disease
  • Participants must be non-smokers (Have not used any nicotine containing products in the last 28 days)
  • Participants must not have a history any severe reactions to medications
  • Participants must not have a history of Retinal Macular Edema or Stargardt Disease

 APPLY NOW

 

LL17035 | Malaria Study

Visit Schedule
#Appointments Only

Participants will be required to attend 7 – 10 appointments. 

 

Part 1
Treatment (Week 1-52)
Part 2
Follow-up
Part 3 (Only if required)
Visit 2 3 4 5 6 7a 7b 8 9 10
Week 1 4 12 24 52 64 64 76 89 104
Hours 2-3 2 3-4 3-4 3-4 3-4 3-4 1-2 1-2 1-2
Payment $  490 700 810 810 210  210 210

 

*Participants who complete the study up to Week 64 will receive in total 

You Get *$2880! 

Inclusion Criteria

  • Healthy males and females between the ages of 18 and 55
  • Must agree to stay in contact with the study site for the duration of the study and up to Week 64 (Visit 7b). Have no current plans to move away from Perth for the duration of the study
  • Must maintain a diary throughout the study
  • No eye conditions or use of prescription eye drops

APPLY NOW

 

Patient Studies

LL17041 | C Diff Vaccine Study

Visit Schedule

Participants will receive 3 vaccination injections over a period of 6 months. There will be a total of 5 outpatient visits to attend, and 2 follow up phone calls across a period of 12 months.

Participants will receive $67 for each visit attended.

Inclusion Criteria

  • Males and females older than 60 years
  • BMI must be between 18-40 kg/m2
  • Must have an increased chance of future contact with healthcare systems by virtue of:
  • At least one inpatient hospitalisation of at least 2 nights in the last 12 months; or
  • At least 2 emergency room visits in the last 12 months; or
  • At least 10 outpatient visits (primary and/or secondary care visits) in the last 12 months; or
  • Taken antibiotics in the last 12 weeks; or
  • Residence in a nursing home

APPLYNOW

LL180511 | Coeliac Study

Help us test a new investigational medication for Coeliac disease!

A gluten-free diet is the only current treatment for Coeliac disease. This study will research whether subcutaneous doses of the trial medication can target the immune response in people with Coeliac disease to protect them from the effects of gluten exposure.  

Visit Schedule

20 x appointments, 1 x phone call & daily diary entries/doses at-home over approximately 7 months.

Screening Period Dosing Period Maintenance Period Follow-Up
Appointments at Linear 1 11 7 1
At-home Questionnaire &/or Dosing 3 19
Phone Call 1
Approximate Appointment Time (At Linear) 9 hrs 1 x 7hrs & 10 x 1hr 4 x 5-6hrs, 2 x 6hrs, 1 x 1-2hrs 1 x 1-2hrs

 

Inclusion Criteria

  • Healthy Males and Females between the ages of 18 and 70
  • Have a diagnosis of Coeliac Disease confirmed with documentation (intestinal biopsy).
  • Have maintained Gluten-free Diet (GFD) for at least 12 consecutive months prior to screening.
  • Willing to consume a moderate amount of gluten (approximately 6 g of gluten protein) once at the screening visit and at a maximum of two other time points for the study.

APPLY NOW